Novartis buys French cancer drug company | November 6, 2017 Issue - Vol. 95 Issue 44 | Chemical & Engineering News
Volume 95 Issue 44 | p. 15 | Concentrates
Issue Date: November 6, 2017

Novartis buys French cancer drug company

Department: Business
Keywords: Mergers & acquisitions, radiopharmaceuticals, Novartis

Novartis will pay $3.9 billion to acquire Advanced Accelerator Applications (AAA), a French radiopharmaceutical firm that makes cancer therapies and diagnostics. AAA’s sales in the first half of 2017 were only $78 million, but analysts suggest that Novartis may replace its patent-expired cancer therapy Sandostatin—which brings in $1.6 billion per year—with AAA’s Lutathera. That therapy was recently approved in Europe to treat gastroenteropancreatic neuroendocrine tumors, the cancer that killed Apple founder Steve Jobs in 2011.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment